{"id":"W4408245591","doi":"10.1111/jdv.20553","title":"Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 <scp>POETYK PSO</scp>‐1, <scp>PSO</scp>‐2 and long‐term extension trials","year":2025,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Adverse effect; Discontinuation; Psoriasis; Placebo; Clinical trial; Internal medicine; Incidence (geometry); Cumulative incidence; Randomized controlled trial; Dosing; Dermatology; Cohort","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005788226,0.0007242851,0.001254298,0.0003756806,0.0004026261,0.001104179,0.0005184584,0.0008253024,0.001424362],"category_scores_gemma":[0.002584776,0.0002933379,0.001767984,0.0003853365,0.0004051002,0.0007227806,0.0003805961,0.001866324,0.0004252055],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008407367,"about_ca_system_score_gemma":0.0009087031,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001081093,"about_ca_topic_score_gemma":0.002216242,"domain_scores_codex":[0.9983152,0.0007852812,0.0001247369,0.0002166128,0.0003429466,0.0002151535],"domain_scores_gemma":[0.9974186,0.0005648314,0.0009022779,0.0002313807,0.0003133449,0.0005696693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5524288,0.02164707,0.04823652,0.001873033,0.007255035,0.0003223857,0.0005281866,0.006962436,0.03407096,0.00026982,0.00847296,0.3179329],"study_design_scores_gemma":[0.3079056,0.3530828,0.3000833,0.0003418332,0.007350752,0.001456157,0.0002093943,0.004321077,0.01212835,0.000623026,0.01234439,0.0001532765],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827999,0.01297127,0.0004000138,0.0002890607,0.00005274684,0.0003843459,0.001149912,0.00005486242,0.001897983],"genre_scores_gemma":[0.9927272,0.003515615,0.0004091882,0.0002761999,0.00008386197,0.0002006511,0.002063797,0.0000137309,0.0007097505],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005788226,"threshold_uncertainty_score":0.0306114,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03773991648713579,"score_gpt":0.2932539044022475,"score_spread":0.2555139879151117,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}